Intensive Glycemic Control for Congestive Heart Failure Exacerbation
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00812253 |
|
Recruitment Status :
Completed
First Posted : December 22, 2008
Results First Posted : August 7, 2014
Last Update Posted : January 2, 2018
|
Sponsor:
Kathleen Dungan
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Kathleen Dungan, Ohio State University
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
Patients with heart failure often have high blood sugar (glucose).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Congestive Heart Failure Diabetes Mellitus | Drug: Intravenous insulin Drug: Subcutaneous insulin | Phase 2 |
Patients with heart failure often have high blood sugar. High glucose contributes to severe hospital complications and even death. Studies suggest that heart failure patients who have high glucose or diabetes do not live as long as patients with normal glucose. In this study, we will determine whether normalizing blood sugars using intravenous insulin short-term will improve outcomes in patients hospitalized for congestive heart failure. We enrolled patients with severe heart failure and randomly assigned them into 2 groups. We used intravenous (given through the vein) insulin to lower blood sugar levels in group 1, and insulin injections in group 2. We determined whether intravenous insulin improved hospital length of stay, rates of readmission, inflammatory markers, and cardiovascular tests that predict mortality in patients with heart failure.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 74 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Intensive Glycemic Control for Congestive Heart Failure Exacerbation |
| Study Start Date : | January 2009 |
| Actual Primary Completion Date : | September 2013 |
| Actual Study Completion Date : | May 2014 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Heart Failure
| Arm | Intervention/treatment |
|---|---|
| Experimental: Intravenous Insulin |
Drug: Intravenous insulin
Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day. |
|
Active Comparator: Subcutaneous Insulin
Basal bolus insulin (4 injections per day)
|
Drug: Subcutaneous insulin
Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day. |
Primary Outcome Measures :
- Hospital Length of Stay [ Time Frame: Days ]Duration of hospitalization in days
Secondary Outcome Measures :
- Hospital Readmission [ Time Frame: 30 days ]All-cause hospital readmission at 30 days after discharge
- Heart Rate Variability [ Time Frame: 72 hours ]High frequency (HF) Heart rate variability (HRV). HRV was assessed with a Bionex system (Mindware, Gahanna, OH). The electrocardiogram was performed in the standard lead II configuration and impedance cardiography was performed using a standard tetrapolar arrangement. Measures were performed at baseline and each morning (0800-1000 hour) during and following the intervention for 7 minutes each. Software (Mindware, Gahanna, OH) was used to derive HF HRV. The middle five minutes of the recordings were scored minute by minute and the first suitable1 minute period was used for calculation. Five minute epochs were not feasible due to an unexpectedly high frequency of ectopy. One minute intervals allow calculation of HF (parasympathetic tone) but not low frequency (combination of sympathetic and parasympathetic tone).
- Change in Quality of Life [ Time Frame: 30 day ]Change in Quality of Life questionnaire measured from baseline (enrollment) to 30 days following discharge. The questionnaire is a self-administered disease-specific questionnaire for patients with HF, comprising 21 items rated on six-point Likert scales, representing different degrees of impact of HF on health related quality of life, from 0 (none) to 5 (very much). It provides a total score (range 0-105, from best to worst HRQoL),
- Brain Natriuretic Peptide (BNP) [ Time Frame: 72 hours ]Brain natriuretic peptide (BNP) was measured at day 3
- Cardiac Output [ Time Frame: 72 hours ]Cardiac output measured using impedance cardiography at 72 hours.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age 18 and above
- Admitted (less than 48 hours) to the OSU Ross Heart Hospital with worsening heart failure
- Hyperglycemia or diabetes. Hyperglycemia is defined as blood glucose greater than 150 mg/dL on at least 2 occasions separated by at least 4 hours apart, insulin use, or HbA1c >6.5%.
Exclusion Criteria:
- Type 1 diabetes
- Receiving comfort care measures only
- Hospital stay expected to be less than 2 days
- Pregnancy
- Prisoners
- Participation in the study on prior hospitalizations
- Acute myocardial infarction within 3 months
- End stage renal or liver disease
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00812253
Locations
| United States, Ohio | |
| The Ohio State University | |
| Columbus, Ohio, United States, 43210 | |
Sponsors and Collaborators
Kathleen Dungan
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
| Principal Investigator: | Kathleen M Dungan, MD | Ohio State University |
| Responsible Party: | Kathleen Dungan, Assistant Professor, Ohio State University |
| ClinicalTrials.gov Identifier: | NCT00812253 History of Changes |
| Other Study ID Numbers: |
2007H0197 1K23DK080891-01A1 ( U.S. NIH Grant/Contract ) |
| First Posted: | December 22, 2008 Key Record Dates |
| Results First Posted: | August 7, 2014 |
| Last Update Posted: | January 2, 2018 |
| Last Verified: | December 2017 |
Keywords provided by Kathleen Dungan, Ohio State University:
|
Heart failure Hyperglycemia Hospital Diabetes Mellitus |
Additional relevant MeSH terms:
|
Diabetes Mellitus Heart Failure Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Heart Diseases |
Cardiovascular Diseases Insulin, Globin Zinc Insulin Hypoglycemic Agents Physiological Effects of Drugs |